Header Logo

Connection

DAVID GRAHAM to Metronidazole

Back to Details
This is a "connection" page, showing publications DAVID GRAHAM has written about Metronidazole.
DAVID GRAHAM
Connection Strength
5.764
Metronidazole
  1. Treatment of Helicobacter pylori in Latin America. Lancet. 2012 Feb 04; 379(9814):408; author reply 408-9.
    View in: PubMed
    Score: 0.368
  2. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter. 2011 Apr; 16(2):139-45.
    View in: PubMed
    Score: 0.347
  3. Diagnosis and Treatment of Helicobacter pylori Infection. Annu Rev Med. 2022 01 27; 73:183-195.
    View in: PubMed
    Score: 0.184
  4. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med. 2001 May 14; 161(9):1217-20.
    View in: PubMed
    Score: 0.175
  5. Nitrofurantoin quadruple therapy for Helicobacter pylori infection: effect of metronidazole resistance. Aliment Pharmacol Ther. 2001 Apr; 15(4):513-8.
    View in: PubMed
    Score: 0.174
  6. Furazolidone- and nitrofurantoin-resistant Helicobacter pylori: prevalence and role of genes involved in metronidazole resistance. Antimicrob Agents Chemother. 2001 Jan; 45(1):306-8.
    View in: PubMed
    Score: 0.171
  7. Recent Developments Pertaining to H. pylori Infection. Am J Gastroenterol. 2021 01 01; 116(1):1-3.
    View in: PubMed
    Score: 0.171
  8. Analysis of rdxA and involvement of additional genes encoding NAD(P)H flavin oxidoreductase (FrxA) and ferredoxin-like protein (FdxB) in metronidazole resistance of Helicobacter pylori. Antimicrob Agents Chemother. 2000 Aug; 44(8):2133-42.
    View in: PubMed
    Score: 0.166
  9. Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study. Aliment Pharmacol Ther. 2000 Jun; 14(6):745-50.
    View in: PubMed
    Score: 0.164
  10. 14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment. Dig Dis Sci. 2020 12; 65(12):3639-3646.
    View in: PubMed
    Score: 0.160
  11. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci. 2000 Jan; 45(1):68-76.
    View in: PubMed
    Score: 0.159
  12. Twice-a-day PPI, tetracycline, metronidazole quadruple therapy with Pylera? or Lactobacillus reuteri for treatment na?ve or for retreatment of Helicobacter pylori. Two randomized pilot studies. Helicobacter. 2019 Dec; 24(6):e12659.
    View in: PubMed
    Score: 0.156
  13. Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States. Int J Antimicrob Agents. 1999 Aug; 12(4):341-7.
    View in: PubMed
    Score: 0.155
  14. Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies. Expert Rev Anti Infect Ther. 2018 09; 16(9):679-687.
    View in: PubMed
    Score: 0.145
  15. One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea. Dig Dis Sci. 1998 Mar; 43(3):464-7.
    View in: PubMed
    Score: 0.140
  16. Helicobacter pylori management in ASEAN: The Bangkok consensus report. J Gastroenterol Hepatol. 2018 Jan; 33(1):37-56.
    View in: PubMed
    Score: 0.139
  17. Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 1997 Oct; 11(5):935-8.
    View in: PubMed
    Score: 0.136
  18. Successful low-dose amoxycillin, metronidazole and omeprazole combination therapy in a population with a high frequency of metronidazole-resistant Helicobacter pylori. Aliment Pharmacol Ther. 1997 Jun; 11(3):523-7.
    View in: PubMed
    Score: 0.133
  19. Increasing role for modified bismuth-containing quadruple therapies for Helicobacter pylori eradication. Minerva Gastroenterol Dietol. 2017 06; 63(2):77-79.
    View in: PubMed
    Score: 0.130
  20. Helicobacter pylori therapy: a paradigm shift. Expert Rev Anti Infect Ther. 2016 06; 14(6):577-85.
    View in: PubMed
    Score: 0.124
  21. Antimicrobial susceptibility testing of Helicobacter pylori. Comparison of E-test, broth microdilution, and disk diffusion for ampicillin, clarithromycin, and metronidazole. Diagn Microbiol Infect Dis. 1996 Jan; 24(1):37-41.
    View in: PubMed
    Score: 0.121
  22. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut. 2015 Nov; 64(11):1715-20.
    View in: PubMed
    Score: 0.118
  23. How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly. Gastroenterol Clin North Am. 2015 Sep; 44(3):537-63.
    View in: PubMed
    Score: 0.116
  24. Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. Aliment Pharmacol Ther. 1995 Apr; 9(2):209-12.
    View in: PubMed
    Score: 0.115
  25. Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol. 1993 Nov; 28(11):939-42.
    View in: PubMed
    Score: 0.104
  26. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014 Feb; 12(2):177-86.e3; Discussion e12-3.
    View in: PubMed
    Score: 0.101
  27. Greater than 95% success with 14-day bismuth quadruple anti- Helicobacter pylori therapy: a pilot study in US Hispanics. Helicobacter. 2012 Oct; 17(5):382-90.
    View in: PubMed
    Score: 0.094
  28. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology. 1992 Feb; 102(2):493-6.
    View in: PubMed
    Score: 0.092
  29. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial. Ann Intern Med. 1991 Aug 15; 115(4):266-9.
    View in: PubMed
    Score: 0.089
  30. Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days. Helicobacter. 2011 Aug; 16(4):295-300.
    View in: PubMed
    Score: 0.089
  31. Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days? Helicobacter. 2011 Apr; 16(2):146-52.
    View in: PubMed
    Score: 0.087
  32. Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol. 2011 Feb; 8(2):79-88.
    View in: PubMed
    Score: 0.086
  33. Helicobacter pylori infection. N Engl J Med. 2010 08 05; 363(6):595-6; author reply 596.
    View in: PubMed
    Score: 0.083
  34. Is there a role for sequential in sequential anti-H. pylori therapy? Gastroenterology. 2006 May; 130(6):1930-1; author reply 1931.
    View in: PubMed
    Score: 0.062
  35. Novel bismuth-metronidazole-tetracycline triple-layer tablet for treatment of Helicobacter pylori. Aliment Pharmacol Ther. 2005 Jan 15; 21(2):165-8.
    View in: PubMed
    Score: 0.056
  36. Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States. Dig Liver Dis. 2004 Jun; 36(6):384-7.
    View in: PubMed
    Score: 0.054
  37. Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. Helicobacter. 2003 Dec; 8(6):626-42.
    View in: PubMed
    Score: 0.052
  38. Management of Helicobacter pylori treatment failures: A large population-based study (HP treatment failures trial). PLoS One. 2023; 18(11):e0294403.
    View in: PubMed
    Score: 0.052
  39. The QUADRATE study: a proposal for a change in the reporting of pharmaceutical supported trials. Gastroenterology. 2003 Aug; 125(2):639; author reply 640-1.
    View in: PubMed
    Score: 0.051
  40. Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen. Helicobacter. 2003 Aug; 8(4):307-9.
    View in: PubMed
    Score: 0.051
  41. Rates of Antimicrobial Resistance in Helicobacter pylori Isolates From Clinical Trial Patients Across the US and Europe. Am J Gastroenterol. 2023 02 01; 118(2):269-275.
    View in: PubMed
    Score: 0.048
  42. DNA sequence analysis of rdxA and frxA from 12 pairs of metronidazole-sensitive and -resistant clinical Helicobacter pylori isolates. Antimicrob Agents Chemother. 2001 Sep; 45(9):2609-15.
    View in: PubMed
    Score: 0.045
  43. Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J Antimicrob Chemother. 2001 Apr; 47(4):459-61.
    View in: PubMed
    Score: 0.043
  44. Isolation and characterization of tetracycline-resistant clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother. 2000 Nov; 44(11):3203-5.
    View in: PubMed
    Score: 0.042
  45. Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother. 2000 Aug; 44(8):2214-6.
    View in: PubMed
    Score: 0.041
  46. Frame-shift mutations in NAD(P)H flavin oxidoreductase encoding gene (frxA) from metronidazole resistant Helicobacter pylori ATCC43504 and its involvement in metronidazole resistance. FEMS Microbiol Lett. 2000 Jul 15; 188(2):197-202.
    View in: PubMed
    Score: 0.041
  47. Furazolidone combination therapies for Helicobacter pylori infection in the United States. Aliment Pharmacol Ther. 2000 Feb; 14(2):211-5.
    View in: PubMed
    Score: 0.040
  48. Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Helicobacter. 1999 Jun; 4(2):106-12.
    View in: PubMed
    Score: 0.038
  49. Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment. Aliment Pharmacol Ther. 2019 06; 49(11):1385-1394.
    View in: PubMed
    Score: 0.038
  50. Resolution of a metaplastic duodenal polyp after cure of Helicobacter pylori infection. J Clin Gastroenterol. 1996 Jul; 23(1):53-4.
    View in: PubMed
    Score: 0.031
  51. Metronidazole, ranitidine and clarithromycin combination for treatment of Helicobacter pylori infection (modified Bazzoli's triple therapy). Aliment Pharmacol Ther. 1996 Feb; 10(1):119-22.
    View in: PubMed
    Score: 0.030
  52. Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate. Helicobacter. 2014 Jun; 19(3):207-13.
    View in: PubMed
    Score: 0.027
  53. Helicobacter pylori infection and exaggerated gastrin release. Effects of inflammation and progastrin processing. Scand J Gastroenterol. 1993 Aug; 28(8):690-4.
    View in: PubMed
    Score: 0.026
  54. Short report: a non-metronidazole triple therapy for eradication of Helicobacter pylori infection--tetracycline, amoxicillin, bismuth. Aliment Pharmacol Ther. 1993 Feb; 7(1):111-3.
    View in: PubMed
    Score: 0.025
  55. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med. 1992 May 01; 116(9):705-8.
    View in: PubMed
    Score: 0.023
  56. Ablation of exaggerated meal-stimulated gastrin release in duodenal ulcer patients after clearance of Helicobacter (Campylobacter) pylori infection. Am J Gastroenterol. 1990 Apr; 85(4):394-8.
    View in: PubMed
    Score: 0.020
  57. Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection. Am J Gastroenterol. 2002 Apr; 97(4):857-60.
    View in: PubMed
    Score: 0.012
  58. Demonstration of unexpected antibiotic resistance of genotypically identical Helicobacter pylori isolates. Clin Infect Dis. 1998 Jul; 27(1):84-9.
    View in: PubMed
    Score: 0.009
  59. Is the sanctuary where Helicobacter pylori avoids antibacterial treatment intracellular? Am J Clin Pathol. 1997 Nov; 108(5):504-9.
    View in: PubMed
    Score: 0.009
  60. Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection. Helicobacter. 1996 Dec; 1(4):243-50.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.